SFESOTCInvestors, NECFiscal year ends December 31
SAFEGUARD SCIENTIFICS INC
Financials through Q4 FY2023, quarter ended Dec 31, 2023Last filing: 10-K on Mar 26, 2024
$0.51+0.01 (+1.98%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2023
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2014 | FY2018 | FY2023 | Trend |
|---|---|---|---|---|
| Current ratio | 21.17 | 1.42 | 4.84 | |
| Interest coverage | -4.3× | -1.1× | – | |
| Diluted shares | 21M | 21M | 16M |
Cash use needs five years of cash flow figures
Safeguard Scientifics does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2023 against fiscal 2022
1of 3 tests passed in fiscal 2023. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-$3.31M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-$3.31M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.79 → 4.84
- No dilutionShare count did not rise16M → 16M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –